Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.76 USD
Change Today -0.09 / -1.86%
Volume 7.2K
CEMI On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 12:42 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

chembio diagnostics inc (CEMI) Snapshot

Open
$5.03
Previous Close
$4.85
Day High
$5.03
Day Low
$4.71
52 Week High
06/12/15 - $5.25
52 Week Low
08/4/14 - $3.04
Market Cap
45.8M
Average Volume 10 Days
15.5K
EPS TTM
$-0.17
Shares Outstanding
9.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHEMBIO DIAGNOSTICS INC (CEMI)

Related News

No related news articles were found.

chembio diagnostics inc (CEMI) Related Businessweek News

No Related Businessweek News Found

chembio diagnostics inc (CEMI) Details

Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company’s products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a Syphilis multiplex test for the detection of antibodies to HIV and Syphilis; and a rapid test for the detection of Hepatitis-C antibodies. Chembio Diagnostics, Inc. sells its products under STAT PAK, SURE CHECK, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with the Oswaldo Cruz Foundation relating to products based on its DPP technology products; and the Centers for Disease Control and Prevention to develop and validate DPP Ebola and DPP Febrile Illness Assays. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

166 Employees
Last Reported Date: 03/5/15
Founded in 1985

chembio diagnostics inc (CEMI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $298.6K
Chief Operating Officer
Total Annual Compensation: $334.6K
Chief Science & Technology Officer
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2014.

chembio diagnostics inc (CEMI) Key Developments

Chembio Diagnostics, Inc.'s DPP HIV 1/2 Assay Receives CE Mark Approval for Rapid Point-Of-Care Detection of HIV

Chembio Diagnostics, Inc. announced that it has received approval for a CE Mark for its DPP HIV 1/2 Assay. The Chembio DPP® HIV 1/2 Assay for rapid, POC detection of HIV is now cleared for commercialization and sale within the 28 member states of the European Union. Chembio's DPP® HIV 1/2 Assay detects HIV antibodies in oral fluid or blood and uses the Company's patented Dual Path Platform (DPP®) technology, which offers excellent sensitivity and specificity. The product's unique SampleTainer® specimen collection bottle is a safe, closed system for collecting potentially infectious samples. The DPP® HIV 1/2 Assay is one of only two FDA-approved, CLIA-waived oral fluid HIV 1/2 rapid tests available in the U.S. The Company expects to launch sales of the product in the European Union in the fourth quarter of 2015.

Chembio Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

Chembio Diagnostics Inc. reported earnings results for the first quarter ended March 31, 2015. For the period, the company reported net income for the first quarter of 2015 was $647,000 or $0.07 per diluted share, compared with net loss of $225,000 or $0.02 per diluted share for the prior year period. Sales of $6 million for January to March, a 7% gain from 2014. Total revenues for the first quarter of 2015 of $6.23 million were up 7.2% compared to total revenues of $5.81 million in the prior year period. Operating loss for the first quarter of 2015 was $875,000 compared with an operating loss of $383,000 for the prior year period. Net cash used in operating activities of $0.94 million as well as investing activities to fund the purchase of the license and deposits on and purchases of fixed assets of $0.86 million.

Chembio Diagnostics, Inc. to Report Q1, 2015 Results on May 07, 2015

Chembio Diagnostics, Inc. announced that they will report Q1, 2015 results at 10:00 AM, US Eastern Standard Time on May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEMI:US $4.76 USD -0.09

CEMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $52.25 USD +0.28
Bio-Rad Laboratories Inc $150.15 USD -0.10
MedMira Inc C$0.04 CAD -0.005
OraSure Technologies Inc $5.42 USD +0.01
Trinity Biotech PLC $18.12 USD +0.10
View Industry Companies
 

Industry Analysis

CEMI

Industry Average

Valuation CEMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMBIO DIAGNOSTICS INC, please visit www.chembio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.